P
revention of morbidity and mortality caused by the human pathogen B. pertussis has effectively relied on national vaccination programs since these were introduced in the 1940s and 1950s (1, 2) . However, during the last decade an increase of whooping cough has been reported (3) (4) (5) (6) (7) (8) (9) . Pertussis, mostly feared for affecting infants too young to be fully vaccinated, is more and more notified among adolescents and adults, who apparently gradually lose their vaccine-induced protection to current B. pertussis strains (2, (10) (11) (12) (13) . Understanding of protective adaptive immunity and its weaknesses is essential for us to be able to improve pertussis vaccination. Despite being implicated in protection against severe pertussis (14, 15) , levels of preexposure human serum antibodies to the major vaccine antigens have never been exclusively correlated with the efficacy of pertussis vaccines (16) (17) (18) . In addition to antibodies, CD4 ϩ T cells contribute to immunological resistance against B. pertussis infection. First, CD4
ϩ T cell responses are essential for avidity maturation of specific B cell responses. Second, murine (19) (20) (21) (22) (23) (24) (25) and human (26) (27) (28) (29) (30) (31) (32) (33) B. pertussis-specific CD4 ϩ T cell immunity has been associated with the secretion of Th1-, Th2-, and Th17-type cytokines capable of arming different types of antimicrobial effector mechanisms, such as the activities of macrophages, eosinophils, and neutrophils, respectively (34) . Unfortunately, information on the fine-specificity and breadth of human B. pertussis-specific CD4 ϩ T cell responses is largely absent, not in the least because of the difficulty of propagating B. pertussis-specific CD4 ϩ T cells in vitro (R. M. Stenger, M. Poelen, and C. A. C. M. van Els, unpublished data). The few human B. pertussis-specific CD4 ϩ T cell epitopes that have been elucidated were all sought only on the basis of known virulence factors (29, (35) (36) (37) . We were interested in gaining nonbiased insight into the natural repertoire of B. pertussis-specific major histocompatibility complex (MHC) class II-presented epitopes, available for T cell recognition at the cell surface of human professional antigen-presenting cells after processing of the whole bacterial proteome. We used a dedicated immunoproteomics method to identify naturally processed and HLA-DR-associated B. pertussis epitopes isolated from human monocyte-derived dendritic cells (MDDC). Stable isotope labeling of B. pertussis biomass prior to loading on MDDC and nanoscale liquid chromatography electrospray ionization mass spectrometry (NanoLC-ESI-MS) were used to sensitively detect pertussis peptide epitopes among thousands of self-peptides in complex peptide fractions (38) . This approach led to the identification of four B. pertussis proteins as sources for dominantly selected and functional CD4 ϩ T cell target epitopes. Interestingly, none of the source proteins was a known virulence factor currently used in acellular pertussis vaccines.
Understanding peculiarities in the display of the natural B.
pertussis CD4 ϩ T cell epitope repertoire on MDDC, such as strong epitope domination, may help to elucidate weaknesses in the human cellular immune response to pertussis and may provide leads on how to design new generations of pertussis assays and vaccines. 14 N and 15 N bacterial biomasses were subjected to quality control. Nanoscale liquid chromatography electrospray ionization tandem mass spectrometry (LC-MS/MS) sequence analysis of trypsin-digested single SDS-PAGE bands of the 14 N and 15 N biomass confirmed uniform stable isotope labeling of pertussis proteins. The optical densities of both wholecell biomasses were measured at 600 nm (A 600 ), and based on these A 600 values, a 1:1 mixture of the 14 N-and 15 N-concentrated whole-cell biomasses was prepared for antigen pulsing of human MDDC (step A in the immunoproteomics strategy, Fig. 1A ).
MATERIALS AND METHODS
Proteins and synthetic peptides. Recombinant P.69 pertactin (P.69 Prn) was expressed and purified from an Escherichia coli construct as previously described (39) . Pertussis toxin (Ptx), filamentous hemagglutinin (FHA), and fimbriae subtypes 2 and 3 (Fim2/3) were purified inhouse according to procedures described in the literature (40) (41) (42) . Purity of all antigens was confirmed by SDS-PAGE.
Synthetic peptides representing the exact HLA-DR eluted peptide sequences, as well as 12 amino acid (aa)-overlapping 18-mer peptides representing the entire protein sequences of 10-kDa chaperonin groES protein (groES) (B. pertussis gene identification number BP3496 [n ϭ 13 peptides]), putative periplasmic protein (PPP) (BP3341 [n ϭ 37 peptides]), adenylosuccinate synthetase (ASS) (BP2188 [n ϭ 71 peptides]), and putative peptidoglycan-associated lipoprotein (PAL) (BP3342 [n ϭ 25 peptides]), respectively, were prepared by solid-phase synthesis using N ␣ -(9-fluorenylmethoxy carbonyl) (FMOC)-protected amino acids and a SYRO II simultaneous multiple peptide synthesizer (MultiSyntech GmbH, Witten, Germany). The purity and identity of the synthesized peptides were assessed by reverse-phase high-performance liquid chromatography and mass spectrometry. Peptides were used as single peptides, combined adjacent peptides representing a broadened epitope region, or peptide pools representing an entire protein.
Immunoblotting. For evaluation of the relative protein contents of known virulence factors, 14 N and 15 N B. pertussis whole-cell preparations were run on SDS-PAGE gels (Pierce, Switzerland) and transferred to nitrocellulose membranes (Schleicher & Schuell). Membranes were washed with Tris/NaCl buffer (pH 7.4) with 0.5% Tween 80 (WS-T), and then probed for 1 h at room temperature (RT) in WS-T with the mouse monoclonal antibodies anti-FHA (31E2), anti-P.69 Prn (Pem4), anti-Ptx S1 (151C1), and anti-Fim2 (136A6) (all from the Dutch National Institute for Public Health and the Environment [43, 44] ). Thereafter, the membranes were washed and incubated for 1 h in WS-T containing alkaline phosphatase-labeled goat-anti-mouse IgG (Southern Biotechnology Associates, Inc.) and 0.5% Protifar (Nutricia, the Netherlands), respectively. Signal was detected with the ready-to-use alkaline phosphatase (AP) conjugate substrate kit (Bio-Rad).
Culturing, antigen pulse, and characterization of MDDC. Immature human MDDC were cultured based on a procedure described by Sallusto et al. (34) . Briefly, 1 ϫ 10 9 PBMC obtained from an HLA-DR2-homozygous blood donor after leukapheresis were seeded at ϳ5 ϫ 10 6 /ml in 150-mm tissue culture dishes (Corning Costar) in Iscove's modified Dulbecco's medium (GibcoBRL) supplemented with 1% fetal bovine serum (HyClone) and penicillin-streptomycin-glutamine (GibcoBRL) at 37°C and 5% CO 2 in a humidified incubator for 2 h. After removal of the nonadherent fraction, adherent cells were further cultured for 6 days in medium containing 500 U/ml recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (PeproTech) and 250 U/ml recombinant human IL-4 (Strathmann Biotech GmbH, Germany). Culture medium and growth factors were refreshed on day 3. On day 6, 1.2 ϫ 10 8 MDDC, still immature, were pulsed with a 1:1 wt/wt mixture of 14 Nand 15 N-concentrated bacterial biomass at an optimized final concentration/A 600 of 0.028 and incubated for 6 h. Thereafter, cells were further cultured and maturated in the continuous presence of antigen, growth factors, and 20 ng/ml lipopolysaccharide (Salmonella abortus equi; Sigma). On day 8, B. pertussis-pulsed and maturated MDDC were harvested and washed four times in PBS, counted, pelleted, and snap frozen before cell lysis and peptide isolation (Fig. 1B) . Maturation of the MDDC was verified using flow cytometry by comparing the expression of CD83, CD40, CD80, and CD86 cell surface markers on day 6 and day 8 MDDC (data not shown).
Isolation and NanoLC-ESI-MS analysis of HLA-DR-associated peptides. B. pertussis-pulsed MDDC were lysed and HLA-DR-peptide complexes were isolated essentially as described previously (38) , using the HLA-DR-specific monoclonal antibody B8.11.2 bound to CNBr-activated Sepharose 4B beads. Peptides were eluted using 10% acetic acid and spun through a 10-kDa cutoff Spinfilter (Millipore, USA) (Fig. 1C) . The filtrate was concentrated to ϳ10 l using a freeze dryer and prefractionated using strong cation exchange (SCX) chromatography. Peptide fractions were reconstituted in a 5% formic acid and 5% dimethyl sulfoxide solution in water containing angiotensin-III and oxytocin (each at a concentration of 250 amol/l) as internal standard peptides and analyzed using NanoLC-ESI-MS/MS, as described earlier (45) (Fig. 1D ). Characteristic heavy and light mass spectral doublets, representing MHC class II-associated peptide epitopes originating from corresponding 14 N and 15 N B. pertussis protein homologues, were allocated in all mass spectra using the MS-Xelerator mass spectral interpretation software (MsMetrix, the Netherlands) (Fig. 1E ). Candidate epitopes were identified by targeted NanoLC-ESI-MS/MS analysis, using identical chromatographic conditions on the same quadrupole time of flight (Q-TOF Ultima API) mass spectrometer operated at optimized collision energy ( Fig. 1F ) and database searching for a sequence match. The expressed levels of epitopes were quantified based on the relative response factor (RRF) of each naturally processed and presented epitope relative to the two additional standard peptides in an SCX fraction and the RRF of the corresponding synthetic analogue compared to these two standard peptides when acquired under identical NanoLC-ESI-MS conditions.
Functional assays to analyze immunogenicity of epitopes. Immunogenicity of epitopes was tested by incubating PBMC in the absence or presence of the indicated synthetic peptide or peptide pool ( was determined as counts per minute (CPM) using a Wallac 1205 betaplate liquid scintillation counter. Results are expressed as stimulation index (SI) from triplicate (donors from the NVI-243 study) or decuple wells (healthy blood donors), calculated as follows: average cpm of PBMC in the presence of peptide(s)/average cpm of PBMC in medium only (direct proliferation) or average cpm of stimulated PBMC cultures in the presence of peptide-pulsed antigen-presenting cells/average cpm of stimulated PBMC cultures in the presence of mock-pulsed antigen-presenting cells (indirect proliferation). SI values of Ն1.5 were considered positive.
For cytokine analysis, human Th1/Th2 and Th17 cytokine Bio-Plex kits (Bio-Rad) were used to determine concentrations of IL-2, IL-4, IL-5, IL-10, IL-12(p70), IL-13, IL-17, tumor necrosis factor alpha (TNF-␣), and gamma interferon (IFN-␥) according to the manufacturer's instructions in (pooled) supernatants taken, as indicated, from those wells out of 40 plated per specific synthetic peptide pool that were visibly activated. Measurements and data analysis were performed with the Bio-Plex system in combination with Bio-Plex manager software. Results are expressed in pg/ml.
For analysis of cross-reactivity, PBMC from a groES 34 -52 -reactive healthy donor were stimulated using groES 34 -52 synthetic peptide for 10 days and then further expanded on 10 ng/ml IL-2 and fresh medium. On day 24, expanded T cells were restimulated for 2 days in triplicate wells using medium only, synthetic peptide representing B. pertussis groES 34 -52 , or synthetic peptide representing Homo sapiens hsp10 40 -58 in the presence of autologous antigen-presenting cells. Then [ 3 H]thymidine was added and incorporation was measured after overnight incubation, as indicated above. Results are expressed as stimulation index (SI) from triplicate wells.
Statistics. The statistical significance of differences in ex vivo lymphoproliferation between groups was calculated with the Student's t test (two-tailed, unequal variance).
RESULTS
Immunoproteomics strategy for sensitive detection of MHC class II-presented B. pertussis epitopes. Foreign MHC class IIpresented epitopes can be isolated from antigen-presenting cells for NanoLC-ESI-MS analysis, but to distinguish them from thousands of self-derived epitopes in complex peptide mixtures is technically highly challenging. To rapidly recognize B. pertussis-specific peptide masses in MHC class II eluates, an immunoproteomics strategy was applied, based on metabolic labeling of the bacterial proteome (schematically illustrated in Fig. 1A to F) . Antigenically, the 14 N and 15 N whole-cell biomasses, harvested in the virulence (bvg ϩ ) phase, were comparable, as was confirmed by immunoblotting of the known virulence factors P.69 pertactin (P.69 Prn), pertussis toxin subunit 1 (PtxS1), filamentous hemagglutinin (FHA), and fimbriae 2 (Fim2) (Fig. 2) . After processing of 1:1 wt/wt mixed bacterial biomasses by MDDC, an HLA-DR-derived peptide sample was obtained, fractionated, and analyzed for the presence of candidate B. pertussis-derived epitopes (Fig. 1D to F) .
B. pertussis PAL, groES, PPP, and ASS identified as dominant source proteins of naturally processed and MHC class II-presented epitopes. An example of such a candidate epitope is given in Fig. 3A and B. Epitope sequencing by targeted nanoscale LC-MS/MS and database matching indeed identified its source protein as a B. pertussis protein, groES (Fig. 3C) . In total, seven naturally processed and presented and hitherto unknown peptides, representing epitopes from four different B. pertussis proteins, including length variants, were identified using isotope-tagged identification (Table 1) . A peptide representing aa residues 103 to 118 from the envelope PAL protein, PAL 103-118 , was the most abundant epitope, with an estimated MHC-peptide copy number of 350 epitopes per MDDC. Lower epitope densities were found for a natural length variant of this epitope and epitopes from groES, PPP, and ASS. No mass spectral doublets were assigned to known B. pertussis virulence factors, despite the fact that these proteins were present in the B. pertussis biomass preparations that were used for MDDC loading (Fig. 2) . Also, data-dependent mass sequencing of peptides present in the eluate did reveal the presence of a wide repertoire of HLA-DR-associated self-sequences (data not shown), but this approach did not yield any additional B. pertussis epitopes.
Naturally processed and HLA-DR-presented epitope regions represent functional CD4
؉ T cell targets. To test the immunogenicity of the processed and HLA-DR2-presented pertussis peptides, PBMC from an HLA-DR-matched blood donor were stimulated ex vivo using synthetic peptides representing the eluted groES 34 -52 , PPP 132-146 , ASS 166 -179 , and PAL 103-118 sequences. In this donor, direct lymphoproliferation could be measured against all four epitopes (Fig. 4) .
We reasoned that the identified peptide sequences may not only represent the exact HLA-DR2-presented epitopes, but may also indicate a broader protein region liberated by proteolysis and possibly containing multiple HLA-DR-binding motifs. We also assumed, since the epitopes were in vitro derived from an experimental whole-cell vaccine, that childhood whole-cell pertussis vaccination could be sufficient to prime CD4 ϩ T cell responses to these epitopes. To evaluate this, PBMC from 20 healthy HLA-DR2-typed adults from a birth cohort associated with whole-cell pertussis vaccination were stimulated with pools of overlapping synthetic peptides representing the epitope regions, including flanking sequences, to encompass adjacent motifs that were predicted to bind a wide array of HLA-DR molecules (46, 47) (data not shown). As summarized in Fig. 5 , direct specific proliferation was observed against all four epitope regions with 30 to 40% over- all responsiveness, not limited to HLA-DR2 ϩ donors only. These data suggest that the extended epitope regions of groES, PPP, ASS, and PAL are recognized in a broader immunogenetic context.
To investigate the type of helper T cell responses associated with epitope immunogenicity, PBMC from responding donors 1, 5, 14, and 19 were cocultured in a new set of restimulations with relevant sets of peptides and cytokine analysis on culture supernatants of wells with activated cultures. All epitope regions were associated with both Th1-(IFN-␥ and TNF-␣) and Th2-type (IL-5 and IL-13) cytokine responsiveness (Fig. 6) . No other cytokines, such as IL-10 or IL-17, were detected.
Specific proliferation as well as cytokine production of expanded CD4 ϩ T cell cultures from various donors could be blocked by monoclonal antibodies against HLA-DR molecules, confirming the involvement of HLA-DR as a restriction element (data not shown). Collectively, these findings indicate that the four HLA-DR2-eluted epitopes represent favorably processed and presented protein regions immunogenic for CD4 ϩ T cells and have a mixed Th1/Th2 cytokine signature.
Epitope-specific responses observed after clinical pertussis infection. To test whether epitopes from groES, PPP, ASS, and PAL were naturally exposed during infection, PBMC obtained from pertussis patients within 12 months after their laboratoryconfirmed clinical episode (n ϭ 30) and from healthy controls (n ϭ 30) were stimulated with overlapping synthetic 18-mer peptides covering the full protein sequences and were assayed for proliferative responses. As illustrated in Fig. 7 , a higher percentage of patients had proliferative responses above the SI cutoff of 1.5
than did healthy controls when tested against peptide sets of groES, PPP, and ASS, but not of PAL. When tested statistically, differences in lymphoproliferation between groups were not significant. The trend, however, may implicate a boosting effect of infection for CD4 ϩ T cell responses of groES, PPP, and ASS. groES 34 -52 -specific CD4 ؉ T cells do not cross-react to the homologous human hsp10 epitope. The 10-kDa chaperonin groES protein is a family member of the low molecular weight heat shock proteins, which are conserved not only between bacteria, but also between humans and other mammal species. The identified B. pertussis groES epitope shows 52.5% sequence homology with the counterpart region on Homo sapiens hsp10 (Fig. 8) . To investigate whether this homology could be immunologically relevant or even underlie autoimmunity, we compared the capacity of groES 34 -52 and its human homologue hsp10 40 -58 to restimulate an in vitro-expanded B. pertussis groES 34 -52 -specific CD4 ϩ T cell bulk culture in the presence of autologous antigen-presenting cells. As shown in Fig. 9 , no recognition of the H. sapiens hsp10 epitope was observed, suggesting that priming of human T cells with the dominantly presented B. pertussis groES region is unlikely to result in cross-reactivity against endogenous tissue.
DISCUSSION
Using an unconventional immunoproteomics approach, we identified hitherto unknown naturally processed and dominantly presented B. pertussis-specific CD4 ϩ T cell epitopes. This approach has two major advantages over strategies aimed at mapping epitopes on predefined protein targets. First, discovery of epitopes is made independent of their protein source, which is especially relevant for pathogens with large proteomes, such as B. pertussis, with more than 3,800 open reading frames (48) . Second, relative abundances and natural length variants of epitopes can be determined, which may have an immunological impact.
The B. pertussis epitopes discovered in this study to be MHC class II presented and immunogenic in humans originated from four different bacterial source proteins localizing to two different subcellular compartments of B. pertussis whole cells. PPP (alternative name, YbgF) and PAL, encoded by adjacent genes on the same operon, are both components of the cell envelope Tol-Pal system, critical for the integrity of the bacterial outer membrane (49) . The 10-kDa chaperonin groES, involved in protein folding and assembly as a homoheptameric ring associated with the chaperonin cpn60, and ASS, catalyzing the first step in the de novo biosynthesis of AMP, are both located in the cytoplasm (48) .
Unexpectedly, none of the dominantly presented epitopes originated from known B. pertussis virulence factors, such as FHA, P.69 Prn, PtxS1, or Fim2, while these proteins were abundantly present in the digested bacterial biomass (Fig. 2) and some encode known T cell epitopes (29, 35, 50, 51) . In fact, preceding B. pertussis harvesting, in-culture gene expression values for groES, PPP, ASS, and PAL were comparably high (groES and PAL) or even lower (PPP and ASS) than those for FHA, P.69 Prn, PtxS1, or Fim2 (52) (B. van der Waterbeemd, personal communication). Therefore, a high antigen load may be favorable, but it is not sufficient for a source protein to dominate in the MHC class II ligandome of MDDC. It is known that for epitopes to be formed, modest but not destructive proteolysis of source proteins (53) and peptide affinity to MHC class II molecules (54) are prerequisites. The groES, PPP, ASS, and epitope regions all have very high predicted epitope binding scores for either HLA-DRB1*1501 or HLA-DRB5*0101, the two HLA-DR molecules expressed on the HLA-DR2 ϩ MDDC (data not shown). Hence, they can be assumed to be strong competitors for binding with epitopes derived from other proteins. Also, other features driving exclusive presentation by MDDC could be involved, such as those described for the Toxoplasma gondii protein profilin, being immunodominant in the CD4 ϩ T cell response to the pathogen solely because of enhanced and selective TLR11-mediated uptake (55) . TLR2 could play a role in the uptake of the lipoprotein PAL (56) (57) (58) (59) (60) (61) (62) , possibly in association with the other Tol-Pal component PPP. TLR2 might also sense groES, eventually via associated compounds (63) (64) (65) . It is unknown whether ASS has innate receptor affinity.
Another unexpected observation was the modest average epitope abundance of the pertussis MHC class II ligands, with estimated numbers of MHC-peptide complexes per cell of 5 to 350. This was dissimilar to the range of MHC class II-presented epitopes we described previously, using an MDDC model with meningococcal outer membrane vesicles as the antigen and applying the same degree of sample prefractionation and analytical sensitivity. HLA-DR-associated meningococcal epitopes isolated from either HLA-DR1 homozygous or HLA-DR2 homozygous MDDC ranged from 30 to 10,000 copies per cell (reference 38 and 
Species
Amino acid sequence B. pertussis groES
H. sapiens hsp10 ϩ T cell-dependent antibody responses, which could be tested in an animal challenge model, is not expected, since the antigens are not surface exposed on the bacterium. However, the antigens could otherwise serve as relevant targets of immune mechanisms. The induced specific CD4 ϩ T cell populations could enhance pertussis immunity via the generation of an inflammatory cytokine milieu, or alternatively, could dampen other
CD4
ϩ T cell specificities through competition for space (68) or through regulation. The CD4 ϩ T cell responses to the identified epitope regions, observed in a considerable proportion of tested individuals, were associated with a mixed Th1/Th2 cytokine profile, i.e., secretion of IFN-␥, TNF-␣, and IL-5 and IL-13, in the absence of IL-10 and IL-17. IFN-␥ and TNF-␣ are both inflammatory cytokines that have been implicated in controlling B. pertussis through potentiating bactericidal activity of macrophages and enhancing phagocytosis by neutrophils (69) (70) (71) , suggesting a role in protection. Notably, (ex)patients had slightly elevated proliferative responses to three of four naturally processed target proteins, possibly indicating that the epitopes were exposed during infection and could play a role in natural CD4
ϩ T cell immunity to B. pertussis. While the data set was possibly too limited to be conclusive and testing more patients' samples could help to settle this point, it is also possible that elevation of T cell responses is confined to a very narrow time span after boosting. The majority of patients in this study were adults who were within 2 months after their formal diagnosis. However, since B. pertussis has a relatively long incubation time (14 to 21 days) and adults are often diagnosed only after a period of prolonged coughing, an early boosting effect of the epitopes on T cell levels could have easily been missed.
Responses to the B. pertussis groES epitope were non-crossreactive to the endogenous human hsp10 homologue. Therefore, dissimilar to the CD4 ϩ T cell epitope cross-reactivities observed for some mycobacterial and human hsp70 protein families, a potential role in autoimmunity or immunoregulation for B. pertussis groES is not envisaged (64) .
In conclusion, an unexpected limited epitope breadth and abundance of human MDDC-presented B. pertussis-specific CD4 ϩ T cell epitopes was found, with a role for other proteins than those that are known virulence factors. Clearly, although being a nonroutine and highly technical approach, immunoproteomics can shed light on classes of otherwise elusive T cell epitopes. These results represent a step toward a more complete characterization of the natural immune response to B. pertussis, involving other specificities than hitherto anticipated. Ultimately, a better understanding of the immunological correlates of protection against whooping cough and their flaws is needed to develop new functional assays and more effective vaccines.
